Sobi has today communicated its offer to acquire
"Investor was instrumental in the creation of Sobi close to 15 years ago. Sobi has during our ownership successfully built a leading hemophilia franchise, broadened its product portfolio and expanded geographically. We support the acquisition of CTI, which is in line with the company's strategy to continue broadening its product portfolio within prioritized areas as well as strengthening its US presence", says Investor's President and CEO
Full details of the bid for CTI are provided in Sobi's offer announcement press release today.
For further information:
Phone +46 70 550 3500
viveka.hirdman-ryrberg@investorab.com
Magnus Dalhammar, Head of Investor Relations,
Phone +46 73 524 2130
magnus.dalhammar@investorab.com
Our press releases can be accessed at www.investorab.com
Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others, ABB,
https://news.cision.com/investor/r/investor-supports-sobi-s-tender-offer-for-cti-biopharma-and-undertakes-to-subscribe-for-its-pro-rata,c3767097
https://mb.cision.com/Main/1084/3767097/2047068.pdf
(c) 2023 Cision. All rights reserved., source